Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02812134

Acronym

IPSAASU

Enrollment

Registered

2016-06-24

Start date

2016-03-26

Completion date

2017-06-16

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Keywords

phosphorus supplementation, FGF23, anorexic, adolescents, undernutrition

Brief summary

Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D). There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

11 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Adolescents aged from 11 to 17 * Follow-up or hospitalisation for anorexia * Overt undernutrition (clinical signs of undernutrition, body mass index and the Waterlow index) * Social security coverage

Exclusion criteria

* Known pre-existing renal disorders * Known constitutional disorders of phosphate-calcium metabolism * Adult patients, legal guardianship, incarceration

Design outcomes

Primary

Measure	Time frame	Description
FGF23	at inclusion and then once a month for 6 months.	Change in the FGF23 level (U/ml) with regard to the exogenous phosphorus intake (doses of Phosphoneuros®, expressed in mg/kg/day)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORLydia LICHTENBERGER, PhD

CHU Amiens

Outcome results